Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Foreign data: Sponsors interested in using data collected outside the U.S. to reduce the requirements for their PMA study or expand their labeling should meet with FDA early on, according to Office of Device Evaluation Interventional Cardiology Device Review Branch Chief Ashley Boam. "In the past, I think we've done a lot of 'well, we have this outside data, now what do we do with it?' We're trying to take the approach now of 'are you planning outside data? Let's talk ahead of time so that we'll know what we can do with it when you finish that study,'" she said Oct. 19 at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C...
You may also be interested in...
FDA Clears Tm Bioscience Cystic Fibrosis Gene Test Via De Novo
FDA's de novo clearance of Tm Bioscience's Tag-It cystic fibrosis test kit paves the way for other CFTR gene mutation detection assays to be categorized as Class II
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.